Literature DB >> 9679965

Galectin-3 is a presurgical marker of human thyroid carcinoma.

F Orlandi1, E Saggiorato, G Pivano, B Puligheddu, A Termine, S Cappia, P De Giuli, A Angeli.   

Abstract

Galectin-3 is a carbohydrate-binding protein endowed with an affinity for beta-galactosides. It has been shown to play an important role in cell-cell and cell-matrix interactions and in pre-mRNA splicing. Furthermore, it is involved in the control of cell growth, neoplastic transformation, and metastasis. Interestingly, high levels of galectin-3 expression have been recently described in malignant thyroid neoplasias, but not in adenomas or in normal thyroid tissue. We investigated galectin-3 expression in human presurgical specimens obtained by fine-needle aspiration biopsy. We analyzed galectin-3 expression by immunoperoxidase staining in both paraffin-embedded cytological thyroid sediments (cell blocks) obtained by fine-needle aspiration biopsy and their histological counterparts. A total of 64 samples were examined: 17 follicular carcinomas; 18 papillary carcinomas; and 29 follicular adenomas. All cell blocks and histological samples of papillary carcinomas expressed high levels of galectin-3 at either the cytoplasmic or nuclear level. Among follicular carcinomas, all histological samples expressed galectin-3, whereas 14 of 17 corresponding cell blocks were positive in the cytoplasm. No evidence of cytoplasmic galectin-3 expression was observed in 26 of 29 follicular adenomas. Hence, cytoplasmic galectin-3 staining seems to be a reliable, easy, and cheap marker for presurgical diagnosis of follicular carcinomas and an even more suitable one for papillary carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679965

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate.

Authors:  R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 2.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 3.  Galectin genes: regulation of expression.

Authors:  Lorenzo Chiariotti; Paola Salvatore; Rodolfo Frunzio; Carmelo B Bruni
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 4.  Diagnostic role of galectin-3 in follicular thyroid tumors.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-03-04       Impact factor: 4.064

5.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 6.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

7.  Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Authors:  Hanan AlSaeid Alshenawy
Journal:  Pathol Oncol Res       Date:  2014-03-23       Impact factor: 3.201

Review 8.  Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

9.  Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark.

Authors:  Martha A Zeiger
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

10.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.